非洲疫苗生态系统全景分析:研发资金、临床试验、监管与生产准备
该卫生政策论文利用公开数据分析非洲疫苗生态系统的研发资金(2007-23年)、临床试验(2007-24年)、监管成熟度和生产准备情况。非洲获得全球疫苗研发资金不足2%,其中95%通过高收入国家渠道;仅8%的全球疫苗临床试验在非洲设有站点;8个国家达到WHO成熟度3级,多国计划建设疫苗生产设施。
要点
- 非洲获得全球疫苗研发资金不足2%,其中95%通过高收入国家渠道。
- 仅8%的全球疫苗临床试验在非洲设有站点。
- 8个国家达到WHO监管成熟度3级,多国计划建设疫苗生产设施。
核心结论
- 非洲疫苗生态系统在研发资金和临床试验参与方面存在显著差距,但监管和生产能力正取得进展,需改善疫苗数据以增强主权和卫生系统韧性。
研究设计与样本
- 卫生政策论文,利用公开数据分析非洲疫苗生态系统的研发资金(2007-23年)、临床试验(2007-24年)、监管成熟度和生产准备情况。
主要发现
- 非洲获得全球疫苗研发资金不足2%,其中95%通过高收入国家渠道。
- 仅8%的全球疫苗临床试验在非洲设有站点。
- 8个国家达到WHO监管成熟度3级,多国计划建设疫苗生产设施。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are vital for global health, and despite bearing the highest burden of infectious diseases, Africa manufactures less than 1% of its vaccine needs. This Health Policy paper offers an overview of Africa's vaccine ecosystem, examining research and development funding, clinical trials, regulatory maturity, and manufacturing readiness with publicly available data. Funding for research and development (2007-23) was analysed with data from the G-FINDER database, which focuses on diseases disproportionately affecting low-income and middle-income countries. Clinical trial activity (2007-24) was assessed with data from multiple sources. Disease burden context was provided by the Global Burden of Disease Study 2021, and regulatory maturity levels were obtained from WHO's list of National Regulatory Authorities. Findings show that Africa received less than 2% of global vaccine research and development funding, with 95% of that funding channelled through high-income countries. Only 8% of global vaccine clinical trials included sites in Africa. Progress in regulatory and manufacturing capacity is emerging, with eight countries reaching WHO maturity level 3 and several countries planning vaccine production facilities. Our findings highlight the need for better vaccine data in Africa and the opportunity to build on existing strengths to reach enhanced sovereignty and resilient health systems.
引用
- Fleck-Vidal C, Le Moal A, Mogeni OD, et al. A landscape analysis of the vaccine ecosystem in Africa: research and development funding, clinical trials, regulation, and manufacturing readiness. Lancet Glob Health. 2025. PMID: 41109268. doi:10.1016/S2214-109X(25)00314-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。